INIS
kinases
100%
tyrosine
100%
myeloid leukemia
64%
patients
56%
risks
43%
in vitro
29%
reviews
28%
atherosclerosis
22%
comparative evaluations
22%
data
18%
biological markers
14%
adriamycin
14%
oncovin
14%
prednisone
14%
matrices
14%
ruptures
14%
safety
14%
migration
13%
adhesion
10%
molecules
10%
viability
10%
concentration
8%
clinical trials
7%
doses
7%
macrophages
6%
production
6%
Keyphrases
Major Molecular Response
14%
Chronic Myeloid Leukemia
14%
Efficacy Biomarkers
14%
BCR-ABL Inhibitors
14%
Atherosclerosis Plaque
14%
Plaque Rupture
14%
Safety Profile
14%
Vascular Safety
14%
Pooled Analysis
14%
Procarbazine
14%
Bleomycin
14%
Adriamycin
14%
Prednisone
14%
Dacarbazine
14%
Advanced Hodgkin's Lymphoma
14%
Leukemia Patients
14%
Oncovin
14%
Arterial Events
10%
Vascular Occlusive Events
10%
Surrogate Biomarkers
7%
Ponatinib
6%
Nilotinib
6%
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
28%
Dasatinib
17%
Chronic Myelogenous Leukemia
16%
In Vitro
14%
Endothelial Cell
14%
Cell Function
14%
Cell Survival
14%
Meta-Analysis
14%
Systematic Review
14%
Prednisone
14%
Procarbazine
14%
Bleomycin
14%
Vinblastine
14%
Imatinib
11%
Ponatinib
10%
Nilotinib
9%
Independent Reviewer
6%
Cell Adhesion Molecule
5%